Jubilant Pharmova reported 16.69% growth in total revenues for the Dec-20 quarter on consolidated basis at Rs1,771.34cr. Jubilant reported smart growth across its 3 verticals of pharmaceuticals, life sciences ingredients and contract research. The quarterly growth was largely driven by CDMO and generics.
The consolidated Profit after tax (PAT) for the Dec-20 quarter was up 52.39% at Rs309.93cr. The sharp rise in profits was due to a fall in the premium paid on early redemption of senior secured notes, which has been shown as an exceptional cost. That has fallen to one-third in the current quarter. As a result, the PAT margins improved sharply from 13.40% in Dec-19 to 17.50% in Dec-20.
Financial highlights for Dec-20 compared yoy and sequentially
|
|
Jubilant Pharmova |
|
|
|
|
|
Rs in Crore |
Dec-20 |
Dec-19 |
YOY |
Sep-20 |
QOQ |
|
Total Income (Rs cr) |
₹ 1,771.34 |
₹ 1,517.98 |
16.69% |
₹ 1,591.35 |
11.31% |
|
Net Profit (Rs cr) |
₹ 309.93 |
₹ 203.38 |
52.39% |
₹ 224.03 |
38.34% |
|
|
|
|
|
|
|
|
Diluted EPS (Rs) |
₹ 19.46 |
₹ 12.77 |
|
₹ 14.06 |
|
|
Net Margins |
17.50% |
13.40% |
|
14.08% |
|
Related Tags: